Phosphorylation of the androgen receptor by PIM1 in hormone refractory prostate cancer

Oncogene

Volumn 32, Issue 34, 2013, Pages 3992-4000

  Ha, S ^a   Iqbal, N J ^a   Mita, P ^a   Ruoff, R ^a   Gerald, W L ^b   Lepor, H ^a   Taneja, S S ^a   Lee, P ^a   Melamed, J ^a   Garabedian, M J ^a   Logan, S K ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

AR; Hormone refractory; Phosphorylation; PIM1; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; CAVEOLIN 2; CYCLIN A1; ENZYME INHIBITOR; INTERLEUKIN 6; PROTEIN KINASE PIM 1; SERINE; SOMATOMEDIN BINDING PROTEIN 5;

ARTICLE; BIOINFORMATICS; CANCER CELL CULTURE; CANCER HORMONE THERAPY; CANCER RECURRENCE; CATALYSIS; CELL STRAIN LNCAP; CELL TYPE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; REPORTER GENE;

AMINO ACID SUBSTITUTION; ANTINEOPLASTIC AGENTS, HORMONAL; BLOTTING, WESTERN; CAVEOLIN 2; CELL LINE, TUMOR; CYCLIN A1; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; MALE; MUTATION; PHOSPHORYLATION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-PIM-1; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SERINE; TISSUE ARRAY ANALYSIS; TRANSCRIPTION FACTORS;

EID: 84883199057     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.412     Document Type: Article

References (55)

1. Ward RD, Weigel NL. Steroid receptor phosphorylation: assigning function to sitespecific phosphorylation 2009; Biofactors 35: 528-536.
2. Lin HK, Wang L, Hu YC, Altuwaijri S, Chang C. Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. EMBO J 2002; 21: 4037-4048.
3. Lin HK, Yeh S, Kang HY, Chang C. Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc Natl Acad Sci USA 2001; 98: 7200-7205.
4. Wen Y, Hu MC, Makino K, Spohn B, Bartholomeusz G, Yan DH et al. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 2000; 60: 6841-6845.
5. Taneja SS, Ha S, Swenson NK, Huang HY, Lee P, Melamed J et al. Cell-specific regulation of androgen receptor phosphorylation in vivo. J Biol Chem 2005; 280: 40916-40924.
6. Saris CJ, Domen J, Berns A. The pim-1 oncogene encodes two related proteinserine/threonine kinases by alternative initiation at AUG and CUG. EMBO J 1991; 10: 655-664.
7. Xie Y, Xu K, Dai B, Guo Z, Jiang T, Chen H et al. The 44 kDa Pim-1 kinase directly interacts with tyrosine kinase Etk/BMX and protects human prostate cancer cells from apoptosis induced by chemotherapeutic drugs. Oncogene 2006; 25: 70-78.
8. Xie Y, Xu K, Linn DE, Yang X, Guo Z, Shimelis H et al. The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells. J Biol Chem 2008; 283: 3349-3356.
9. Mochizuki T, Kitanaka C, Noguchi K, Muramatsu T, Asai A, Kuchino Y. Physical and functional interactions between Pim-1 kinase and Cdc25A phosphatase. Implications for the Pim-1-mediated activation of the c-Myc signaling pathway. J Biol Chem 1999; 274: 18659-18666.
10. Morishita D, Katayama R, Sekimizu K, Tsuruo T, Fujita N. Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels. Cancer Res 2008; 68: 5076-5085.
11. Aho TL, Sandholm J, Peltola KJ, Mankonen HP, Lilly M, Koskinen PJ. Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site. FEBS Lett 2004; 571: 43-49.
12. Cibull TL, Jones TD, Li L, Eble JN, Ann Baldridge L, Malott SR et al. Overexpression of Pim-1 during progression of prostatic adenocarcinoma. J Clin Pathol 2006; 59: 285-288.
13. Valdman A, Fang X, Pang ST, Ekman P, Egevad L. Pim-1 expression in prostatic intraepithelial neoplasia and human prostate cancer. Prostate 2004; 60: 367-371.
14. van Lohuizen M, Verbeek S, Krimpenfort P, Domen J, Saris C, Radaszkiewicz T et al. Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors. Cell 1989; 56: 673-682.
15. Verbeek S, van Lohuizen M, van der Valk M, Domen J, Kraal G, Berns A. Mice bearing the E mu-myc and E mu-pim-1 transgenes develop pre-B-cell leukemia prenatally. Mol Cell Biol 1991; 11: 1176-1179.
16. Ellwood-Yen K, Graeber TG, Wongvipat J, Iruela-Arispe ML, Zhang J, Matusik R et al. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 2003; 4: 223-238.
17. Wang J, Kim J, Roh M, Franco OE, Hayward SW, Wills ML et al. Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma. Oncogene 2010; 29: 2477-2487.
18. Zhou Z, Flesken-Nikitin A, Corney DC, Wang W, Goodrich DW, Roy-Burman P et al. Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. Cancer Res 2006; 66: 7889-7898.
19. Koike N, Maita H, Taira T, Ariga H, Iguchi-Ariga SM. Identification of heterochromatin protein 1 (HP1) as a phosphorylation target by Pim-1 kinase and the effect of phosphorylation on the transcriptional repression function of HP1(1). FEBS Lett 2000; 467: 17-21.
20. Wang Z, Bhattacharya N, Mixter PF, Wei W, Sedivy J, Magnuson NS. Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1 kinase. Biochim Biophys Acta 2002; 1593: 45-55.
21. Chen WW, Chan DC, Donald C, Lilly MB, Kraft AS. Pim family kinases enhance tumor growth of prostate cancer cells. Mol Cancer Res 2005; 3: 443-451.
22. Cuypers HT, Selten G, Quint W, Zijlstra M, Maandag ER, Boelens W et al. Murine leukemia virus-induced T-cell lymphomagenesis: integration of proviruses in a distinct chromosomal region. Cell 1984; 37: 141-150.
23. Ha S, Ruoff R, Kahoud N, Franke TF, Logan SK. Androgen receptor levels are upregulated by Akt in prostate cancer. Endocr Relat Cancer 2011; 18: 245-255.
24. Xin L, Teitell MA, Lawson DA, Kwon A, Mellinghoff IK, Witte ON. Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor. Proc Natl Acad Sci USA 2006; 103: 7789-7794.
25. Kim J, Roh M, Abdulkadir SA. Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity. BMC Cancer 2010; 10: 248.
26. Beharry Z, Mahajan S, Zemskova M, Lin Y-W, Tholanikunnel BG, Xia Z et al. The Pim protein kinases regulate energy metabolism and cell growth. Proc Natl Acad Sci USA 2011; 108: 528-533.
27. Xia Z, Knaak C, Ma J, Beharry ZM, McInnes C, Wang W et al. Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases. J Med Chem 2009; 52: 74-86.
28. Rennie PS, Bruchoky N, Leco KJ, Sheppard PC, McQueen SA, Cheng H et al. Characterization of two cis-acting DNA elements involved in the androgen regulation of the probasin gene. Mol Endocrinol 1993; 7: 23-36.
29. Ha S, Ruoff R, Kahoud N, Logan SK, Franke TF. Androgen receptor levels are upregulated by Akt in prostate cancer. Endocr Relat Cancer 2011; Feb: 11.
30. Thompson J, Peltola KJ, Koskinen PJ, Janne OA, Palvimo JJ. Attenuation of androgen receptor-dependent transcription by the serine/threonine kinase Pim-1. Lab Invest 2003; 83: 1301-1309.
31. Song H, Zhang B, Watson MA, Humphrey PA, Lim H, Milbrandt J. Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis. Oncogene 2009; 28: 3307-3319.
32. Bowen C, Bubendorf L, Voeller HJ, Slack R, Willi N, Sauter G et al. Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression1,2. Cancer Res 2000; 60: 6111-6115.
33. Shen MM, Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev 2010; 24: 1967-2000.
34. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001; 412: 822-826.
35. Su Y, Wagner ER, Luo Q, Huang J, Chen L, He BC et al. Insulin-like growth factor binding protein suppresses tumor growth and metastasis of human osteosarcoma. Oncogene 2011; 30: 3907-3917.
36. Wegiel B, Bjartell A, Ekberg J, Gadaleanu V, Brunhoff C, Persson JL. A role for cyclin A1 in mediating the autocrine expression of vascular endothelial growth factor in prostate cancer. Oncogene 2005; 24: 6385-6393.
37. Wegiel B, Bjartell A, Tuomela J, Dizeyi N, Tinzl M, Helczynski L et al. Multiple cellular mechanisms related to cyclin A1 in prostate cancer invasion and metastasis. J Natl Cancer Inst 2008; 100: 1022-1036.
38. Kim O, Jiang T, Xie Y, Guo Z, Chen H, Qiu Y. Synergism of cytoplasmic kinases in IL6-induced ligand-independent activation of androgen receptor in prostate cancer cells. Oncogene 2004; 23: 1838-1844.
39. Twillie DA, Eisenberger MA, Carducci MA, Hseih W-S, Kim WY, Simons JW. Interleukin-6: A candidate mediator of human prostate cancer morbidity. Urology 1995; 45: 542-549.
40. Michalaki V, Syrigos K, Charles P, Waxman J. Serum levels of IL-6 and TNF-[alpha] correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer 2004; 90: 2312-2316.
41. Drachenberg DE, Elgamal AAA, Rowbotham R, Peterson M, Murphy GP. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate 1999; 41: 127-133.
42. Chun JY, Nadiminty N, Dutt S, Lou W, Yang JC, Kung H-J et al. Interleukin-6 regulates androgen synthesis in prostate cancer cells. Clin Cancer Res 2009; 15: 4815-4822.
43. Gould ML, Williams G, Nicholson HD. Changes in caveolae, caveolin, and polymerase 1 and transcript release factor (PTRF) expression in prostate cancer progression. Prostate 2010; 70: 1609-1621.
44. Chen S, Gulla S, Cai C, Balk SP. Androgen receptor serine 81 phosphorylation mediates chromatin binding and transcriptional activation. J Biol Chem 2012; 287: 8571-8583.
45. Chen W, Dang T, Blind RD, Wang Z, Cavasotto CN, Hittelman AB et al. Glucocorticoid receptor phosphorylation differentially affects target gene expression. Mol Endocrinol 2008; 22: 1754-1766.
46. Zippo A, De Robertis A, Serafini R, Oliviero S. PIM1-dependent phosphorylation of histone H3 at serine 10 is required for MYC-dependent transcriptional activation and oncogenic transformation. Nat Cell Biol 2007; 9: 932-944.
47. Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2007; 39: 41-51.
48. Hendriksen PJ, Dits NF, Kokame K, Veldhoven A, van Weerden WM, Bangma CH et al. Evolution of the androgen receptor pathway during progression of prostate cancer. Cancer Res 2006; 66: 5012-5020.
49. Qin J, Liu X, Laffin B, Chen X, Choy G, Jeter CR et al. The PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration. Cell Stem Cell 2012; 10: 556-569.
50. Payne H, Cornford P. Prostate-specific antigen: an evolving role in diagnosis, monitoring, and treatment evaluation in prostate cancer. Urol Oncol 2011; 29: 593-601.
51. Mumenthaler SM, Ng PY, Hodge A, Bearss D, Berk G, Kanekal S et al. Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes. Mol Cancer Ther 2009; 8: 2882-2893.
52. Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A et al. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer 1999; 81: 242-251.
53. Gstaiger M, Luke B, Hess D, Oakeley EJ, Wirbelauer C, Blondel M et al. Control of nutrient-sensitive transcription programs by the unconventional prefoldin URI. Science 2003; 302: 1208-1212.
54. Garraway IP, Sun W, Tran CP, Perner S, Zhang B, Goldstein AS et al. Human prostate sphere-forming cells represent a subset of basal epithelial cells capable of glandular regeneration in vivo. Prostate 2010; 70: 491-501.
55. Nwachukwu JC, Mita P, Ruoff R, Ha S, Wang Q, Huang SJ et al. Genome-wide impact of androgen receptor trapped clone-27 loss on androgen-regulated transcription in prostate cancer cells. Cancer Res 2009; 69: 3140-3147.